Viloxazine extended-release (ER) is a non-stimulant medication approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric and adult populations. While numerous randomized controlled trials (RCTs) have demonstrated its efficacy in young populations, evidence specific to adolescents remains limited, and even fewer data on adults exist. This systematic review and meta-analysis evaluates the efficacy and tolerability of viloxazine ER in adolescents and adults through…
